Compare LEG & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEG | PHVS |
|---|---|---|
| Founded | 1883 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | 2021 |
| Metric | LEG | PHVS |
|---|---|---|
| Price | $11.75 | $27.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $10.50 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 1.4M | 205.4K |
| Earning Date | 02-12-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $4,172,899,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.48 | $11.51 |
| 52 Week High | $12.77 | $29.80 |
| Indicator | LEG | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 57.92 |
| Support Level | $11.99 | $26.73 |
| Resistance Level | $12.77 | $28.20 |
| Average True Range (ATR) | 0.36 | 1.35 |
| MACD | -0.10 | 0.16 |
| Stochastic Oscillator | 10.09 | 76.69 |
Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.